The impact of palbociclib (Ibrance) on overall survival for metastatic breast cancer patients in the PALOMA-3 trial

https://www.facingourrisk.org/XRAY/palbociclib-overall-survival-metastatic-breast-cancer

Full article: https://www.nejm.org/doi/full/10.1056/NEJMoa1810527

The PALOMA-3 clinical trial showed that a new CDK4/6 inhibitor in combination therapy improved progression-free survival of women treated for hormone receptor-positive, HER2-negative advanced or metastatic breast cancer in women with prior disease progression after endocrine therapy. This XRAYS reviews a newly published study in the New England Journal of Medicine that looks at overall survival in the original PALOMA-3 study. (1/23/19)

Questions To Ask Your Health Care Provider

What treatment therapy or therapies are best for my circumstance?
Are there combination therapies that I should consider?
Should I consider treatment with a CDK4/6 inhibitor for my metastatic breast cancer?
What are the pros and cons of various treatments for my metastatic breast cancer?
Are there clinical trials enrolling participants with metastatic breast cancer that are appropriate for me?

About FORCE

FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.